Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Dystrophia myotonica protein kinase (DMPK) is a serine/threonine-specific protein kinase that plays a crucial role in muscle, heart, and brain cells. It is encoded by the DMPK gene and is most notable for its involvement in the pathogenesis of myotonic dystrophy type 1 (DM1). DMPK acts as a non-receptor serine/threonine protein kinase essential for maintaining skeletal muscle structure and function. It regulates intracellular communication and modulates the production/function of key structures inside muscle cells. DM1 results from an unstable CTG trinucleotide repeat expansion within the DMPK gene, leading to toxic RNA species that disrupt normal cellular function. Decreased expression or loss-of-function mutations can contribute directly to disease pathology.
Modulation of pathways affected by toxic RNA foci generated from mutant transcripts; Inhibition of myosin phosphatase
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dystrophia Myotonica Protein Kinase (DMPK).